Does ITI Actually Work in Hemophilia B – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Shaoyu Yin et al, adding:
“Immune tolerance induction (ITI) in hemophilia B: does it actually work?
This systematic review makes one thing clear: ITI in hemophilia B is unpredictable and risky.
What the data show:
Across 125 patients:
- Success rates vary wildly (from 12.8 pecent to 100 percent)
- Time to tolerance: approximately 1 to 19 months
- Multiple attempts often needed
The real challenge: safety
Adverse events are not rare, they’re defining:
- Allergic reactions: from 0 to 100 percent
- Nephrotic syndrome: from 0 to 33 percent
These complications are far more common than in hemophilia A.
This is the key issue:
- No standardized definition of ‘success.’
- No uniform ITI protocol
- Small, heterogeneous cohorts
We’re comparing apples to oranges across studies.
Clinical insight
- ITI can still work, even after failure or allergic reactions
- But nephrotic syndrome is a major red flag (often treatment-limiting)
- Immunosuppression is widely used but doesn’t eliminate risk
Big picture
Unlike hemophilia A, where ITI is established: Hemophilia B remains a high-risk, low-predictability space
And until we standardize protocols: We’re optimizing therapy without a common playbook.”
Title: Treatment outcomes, safety, and characteristics of immune tolerance induction in patients with hemophilia B and inhibitors: a systematic review
Authors: Shaoyu Yin, Jiahong Wu, Wen Yang, Hongli Mu, Yuexing Peng, Haoran Lu, Rong Li, Hui Bi, Zeping Zhou
Read the Full Article on Research and Practice in Thrombosis and Haemostasis
See more in the gallery.
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers